Skip to content

RXO RXO Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

SoundHound AI, Inc. logo
SoundHound AI, Inc.SOUN
$0-100%
STU
StubHub Holdings, Inc.STUB
$2.06M
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$126K-60.5%
NTS
Netskope, Inc. Class A Common StockNTSK
$0-100%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$578K
Hinge Health, Inc. logo
Hinge Health, Inc.HNGE
$0-100%

Other financials

Income statement

See full
Revenue$1.4B-0.6%
Gross profit$254.0M-9.3%
Operating income-$28.0M+6.7%
Net income-$36.0M-16.1%
EPS (diluted)-$0.21-16.7%

Balance sheet

See full
Cash & equivalents$22.0M+37.5%
Total debt$716.0M+2.0%
Total equity$1.5B-4.9%
Total assets$3.3B-1.1%

Cash flow

See full
Operating cash flow-$7.0M-250%
CapEx$17.0M+13.3%
Free cash flow-$24.0M-41.2%

Valuation

See full
Market cap$4.2B-23.0%

Profitability

See full
Gross margin19.3%-1.5pp
Operating margin-1.3%-0.1pp
Net margin-1.8%-0.8pp
FCF margin-1.4%

Returns & leverage

See full
Return on equity-6.8%-2.9pp
Debt / equity0.5×0.0×
Current ratio1.3×0.0×

Where this comes from

Reported directly by RXO in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: RXO’s 10-K, filed February 9, 2026, on SEC EDGAR. View the filing →

Ask your AI about RXO's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RXO's payments of stock issuance costs?
RXO (RXO) reported payments of stock issuance costs of $250K in Q4 2025.
How has RXO's payments of stock issuance costs changed year-over-year?
RXO's payments of stock issuance costs decreased by 96.7% year-over-year, from $7.5M to $250K.
What does payments of stock issuance costs mean?
Includes direct costs such as legal, accounting, and underwriting fees incurred to issue new equity. Monitoring these costs helps assess the efficiency of the company's capital-raising activities and the impact of financing decisions on net cash flow. High issuance costs relative to proceeds may indicate unfavorable market terms or complex transaction structures.